tiprankstipranks
Eterna Therapeutics (ERNA)
NASDAQ:ERNA
US Market

Eterna Therapeutics (ERNA) Stock Price & Analysis

213 Followers

ERNA Stock Chart & Stats

Day’s Range$1.94 - $2.2
52-Week Range― - ―
Previous Close$2.14
Volume9.87K
Average Volume (3M)N/A
Market Cap
$11.58M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)N/A
BetaN/A
Apr 14, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Financials

Annual

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Website Traffic

Sorry, No Data Available
There is no website visitor data available for this stock.
---

ERNA FAQ

What was Eterna Therapeutics’s price range in the past 12 months?
Currently, no data Available
What is Eterna Therapeutics’s market cap?
Currently, no data Available
When is Eterna Therapeutics’s upcoming earnings report date?
Eterna Therapeutics’s upcoming earnings report date is Apr 14, 2023 which is 378 days ago.
    How were Eterna Therapeutics’s earnings last quarter?
    Eterna Therapeutics released its earnings results on Nov 08, 2022. The company reported -$2.488 earnings per share for the quarter, missing the consensus estimate of -$2.2 by -$0.288.
      Is Eterna Therapeutics overvalued?
      According to Wall Street analysts Eterna Therapeutics’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
        Does Eterna Therapeutics pay dividends?
        Eterna Therapeutics does not currently pay dividends.
        What is Eterna Therapeutics’s EPS estimate?
        Eterna Therapeutics’s EPS estimate is -$2.4.
          How many shares outstanding does Eterna Therapeutics have?
          Currently, no data Available
          What happened to Eterna Therapeutics’s price movement after its last earnings report?
          Eterna Therapeutics reported an EPS of -$2.488 in its last earnings report, missing expectations of -$2.2. Following the earnings report the stock price went up 3.67%.
            Which hedge fund is a major shareholder of Eterna Therapeutics?
            Currently, no hedge funds are holding shares in ERNA
            ---

            Eterna Therapeutics Stock Smart Score

            N/A
            Not Ranked
            1
            2
            3
            4
            5
            6
            7
            8
            9
            10

            Technicals

            SMA
            Positive
            20 days / 200 days
            Momentum
            -34.95%
            12-Months-Change

            Fundamentals

            Return on Equity
            -302.20%
            Trailing 12-Months
            Asset Growth
            120.53%
            Trailing 12-Months

            Company Description

            Eterna Therapeutics

            NTN Buzztime, Inc. engages in the provision of entertainment and innovative technology services. It offers entertainment, live events, dining, marketing, hardware, and pricing products. It also includes performance analytics and secure payment with Europay, MasterCard, and Visa chip readers or with near-field communication (NFC) technology to accept Apple, Android, and Samsung Pay. The company was founded in 1984 and is headquartered in Carlsbad, CA.
            ---
            Similar Stocks
            Company
            Price & Change
            Follow
            Amarin
            ADMA Biologics
            Aclaris Therapeutics
            Anavex Life Sciences
            Popular Stocks
            ---
            What's Included in PREMIUM?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis